Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

To determine the long-term effects of ranibizumab (RBZ) in patients with diabetic macular edema (DME). Prospective, randomized, interventional, multicenter clinical trial. One hundred twenty-six patients with DME. Subjects were randomized 1:1:1 to receive 0.5 mg RBZ at baseline and months 1, 3, and...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Ophthalmology (Rochester, Minn.) Ročník 117; číslo 11; s. 2146
Hlavní autori:	Nguyen, Quan Dong, Shah, Syed Mahmood, Khwaja, Afsheen A, Channa, Roomasa, Hatef, Elham, Do, Diana V, Boyer, David, Heier, Jeffery S, Abraham, Prema, Thach, Allen B, Lit, Eugene S, Foster, Bradley S, Kruger, Erik, Dugel, Pravin, Chang, Thomas, Das, Arup, Ciulla, Thomas A, Pollack, John S, Lim, Jennifer I, Eliott, Dean, Eliot, Dean, Campochiaro, Peter A
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.11.2010
Predmet:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Combined Modality Therapy Diabetic Retinopathy - drug therapy Fluorescein Angiography Humans Injections Laser Coagulation Macular Edema - drug therapy Prospective Studies Ranibizumab Retreatment Time Factors Tomography, Optical Coherence Treatment Outcome Visual Acuity - physiology Vitreous Body
ISSN:	1549-4713, 1549-4713
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!